Arcadia Biosciences, Inc. · LSX:A3D7B0

Arcadia Biosciences, Inc. financial statements

Arcadia Biosciences, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue4.86M5.04M4.45M7.42M6.78M8.03M1.17M1.46M4.03M3.19M
Cost of revenue3.10M2.96M2.17M6.10M8.71M5.20M885.0K661.0K283.0K895.0K
Gross profit1.76M2.08M2.28M1.32M-1.93M2.83M284.0K803.0K3.74M2.29M
Research and development9.00K53.0K64.0K1.51M3.89M7.96M7.10M6.07M7.41M8.66M
Selling, general and administrative7.00M9.64M8.23M15.0M22.9M16.5M13.6M11.6M10.7M12.3M
Operating income-2.50M-3.65M-6.10M-14.0M-35.5M-12.8M-19.4M-16.9M-14.3M-18.6M
Depreciation and amortization32.0K58.0K111.0K439.0K929.0K632.0K194.0K154.0K279.0K304.0K
EBITDA-2.47M-3.59M-5.99M-13.6M-34.6M-12.1M-19.2M-16.7M-14.0M-18.3M
Interest expense289.0K20.0K47.0K5.00K2.56M747.0K1.32M
Income before tax-2.33M-4.31M-5.32M-10.8M-16.1M-6.15M-28.9M-13.5M-15.7M-19.6M
Income tax8.00K8.00K8.00K14.0K2.00K-124.0K2.00K10.0K26.0K25.0K
Net income-2.34M-7.04M-14.0M-15.4M-14.7M-4.66M-28.8M-13.5M-15.7M-19.6M
Earnings per share, basic-1.71-5.17-11.29-25.65-27.56-0.47-4.53-3.58-7.28-8.85
Earnings per share, diluted-1.71-5.17-11.29-25.65-27.56-0.47-4.53-3.58-7.28-8.85

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents259.0K4.24M6.52M20.6M28.7M14.0M8.42M12.0M9.13M2.01M
Short-term investments4.30M05.12M0011.6M16.9M9.82M3.90M48.5M
Receivables425.0K1.18M514.0K1.22M1.37M1.41M602.0K165.0K1.23M349.0K
Inventory1.21M904.0K837.0K2.32M4.43M3.81M1.79M181.0K229.0K252.0K
Current assets6.36M9.24M15.0M25.4M35.4M31.7M28.4M22.9M15.0M52.2M
Property, plant and equipment8.00K41.0K70.0K680.0K2.29M3.54M1.80M395.0K299.0K508.0K
Goodwill0408.0K000
Total assets6.55M13.5M19.7M28.9M43.9M47.3M32.6M24.0M16.6M56.6M
Accounts payable1.45M703.0K801.0K905.0K1.41M726.0K492.0K285.0K366.0K222.0K
Current liabilities2.06M2.56M3.59M4.21M5.04M6.31M5.71M3.05M3.52M3.13M
Long-term debt02.10M107.0K025.1M
Total debt155.0K1.01M2.02M02.10M107.0K0025.1M
Total liabilities2.41M7.29M7.00M8.02M12.7M18.8M24.2M11.2M8.56M34.4M
Shareholders' equity4.14M6.22M12.8M21.0M31.1M27.7M7.71M12.8M8.01M22.2M
Shares outstanding1.37M1.36M1.29M616.1K554.6K13.5M8.65M4.77M2.13M2.22M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-4.70M-9.63M-15.3M-14.0M-25.9M-30.2M-17.2M-13.6M-14.0M-17.1M
Capital spending0-16.0K-5.00K-72.0K-1.01M-2.33M-1.48M-250.0K-79.0K-231.0K
Free cash flow-4.70M-9.64M-15.3M-14.0M-26.9M-32.6M-18.7M-13.9M-14.0M-17.3M
Cash from investing750.0K7.34M-4.34M1.42M16.6M17.3M-8.37M-5.97M47.2M-5.30M
Cash from financing6.00K9.00K5.51M4.52M21.9M20.6M22.0M22.5M-26.1M396.0K
Dividends paid00
Share buybacks25.1M9.42M5.29M10.0M24.0K442.0K
Change in cash-3.98M-2.28M-14.1M-8.04M12.6M7.63M-3.58M2.87M7.11M-22.0M